LncRNA UCA1 mediates Cetuximab resistance in Colorectal Cancer via the MiR-495 and HGF/c-MET Pathways

Background: Cetuximab is one of the most widely used monoclonal antibodies to treat patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC). Unfortunately, cetuximab resistance often occurs during targeted therapy. However, the underlying epigenetic mechanisms remain unclear. Our previo...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Heng-heng, Zhang, Xin-chen, Wei, Xiao-li, Zhang, Wen-jie, Du, Xiao-xue, Huang, Peng, Chen, Hao, Bai, Lu, Zhang, Hong-feng, Han, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692674/
https://www.ncbi.nlm.nih.gov/pubmed/34976187
http://dx.doi.org/10.7150/jca.65687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692674/
https://www.ncbi.nlm.nih.gov/pubmed/34976187
http://dx.doi.org/10.7150/jca.65687

Ejemplares similares